Stoke Therapeutics, Inc. 8-K

What Happened
Stoke Therapeutics announced that on April 3, 2026 its Board increased to ten directors and appointed G. Clare Kahn, Ph.D. as a Class I director, effective immediately. Dr. Kahn will serve until the 2026 Annual Meeting (the next meeting at which Class I directors are elected). The company issued a press release about the appointment on April 7, 2026.

Key Details

• Board size increased to 10 directors; Dr. G. Clare Kahn appointed as Class I director (effective April 3, 2026).
• Committee roles: appointed to the Nominating & Corporate Governance Committee and named Chair of the Research & Development Committee.
• Compensation: annual cash retainer of $45,000 under the Company’s non-employee director program.
• Equity grant: one-time initial stock option to buy 30,782 shares (target ASC 718 grant‑date fair value ≈ $724,000) vesting in 12 substantially equal quarterly installments.
• Governance notes: Board determined Dr. Kahn qualifies as an independent director; she entered the Company’s standard director indemnity agreement and has no related‑party transactions required to be disclosed.

Why It Matters
This filing signals a governance and expertise addition—Dr. Kahn joins Stoke’s board and will lead the Research & Development Committee, which is relevant for a biotech company where R&D oversight is material. The company recorded a meaningful equity grant (ASC 718 fair value ≈ $724k) and a $45k annual cash retainer, both of which are standard director compensations investors may monitor as part of corporate governance and dilution/expense considerations. The appointment was disclosed via an 8‑K and press release.